25.76 0.00 (0.00%)
After hours: 5:00PM EDT
|Bid||25.74 x 900|
|Ask||25.71 x 1800|
|Day's Range||24.97 - 25.89|
|52 Week Range||24.97 - 50.44|
|Beta (3Y Monthly)||1.08|
|PE Ratio (TTM)||91.67|
|Earnings Date||Aug 19, 2019 - Aug 23, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||35.42|
Myriad Genetics Inc NASDAQ/NGS:MYGNView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and declining Bearish sentimentShort interest | NeutralShort interest is moderately high for MYGN with between 10 and 15% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on May 9. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding MYGN are favorable, with net inflows of $2.94 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
SALT LAKE CITY, May 14, 2019 -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it will present results from multiple studies at.
Myriad Genetics, Inc. (MYGN), a global leader in personalized medicine, today announced that the EndoPredict® test (EPclin) identifies women with early-stage breast cancer who can safely forgo extended endocrine therapy five years after diagnosis. Findings from the study were published in the journal Clinical Cancer Research.
Myriad Genetics (MYGN) observes strong year-over-year revenue growth in EndoPredict, Hereditary Cancer and Prolaris testing as well as pharmaceutical and clinical service segments.
Myriad (MYGN) delivered earnings and revenue surprises of 4.55% and -0.81%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Salt Lake City-based company said it had profit of 9 cents. Earnings, adjusted for one-time gains and costs, came to 46 cents per share. The results topped Wall Street expectations. ...
Total Third-Quarter Revenues of $216.6 Million, Up 18 PercentThird-Quarter Diluted EPS of $0.09 and Adjusted EPS of $0.46, Up 35 Percent SALT LAKE CITY, May 07, 2019 -- Myriad.
SALT LAKE CITY, May 01, 2019 -- Myriad Genetics, Inc. (NASDAQ: MYGN), a worldwide leader in personalized medicine, today announced that Kroger Prescription Plans, will provide.
SALT LAKE CITY, May 01, 2019 -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced that it will be presenting at two.
Myriad Genetics, Inc. (MYGN), a global leader in personalized medicine, today announced an international team of cancer researchers has found that EndoPredict® test accurately predicts which women with ER-positive, HER2-negative breast cancer will benefit from adjuvant chemotherapy. Findings from the study were published today in the journal Breast Cancer Research and Treatment. This study evaluated the ability of the EndoPredict test (EPclin) to predict chemotherapy benefit based on the analysis of the 10-year distant recurrence rate (i.e., metastasized cancer) in women with ER-positive, HER2-negative breast cancer who received five years of endocrine therapy (ET) alone or in combination with chemotherapy (ET+C). Data from 3,746 women (2,630 on ET alone and 1,116 on ET+C) were included in the analysis. The study found that women with a high EndoPredict score (i.e., 3.3) and who received ET+C had significantly lower 10-year recurrence risk than those on ET alone (Graph 1). However, there were no significant differences between ET+C and ET for patients with low EndoPredict scores, suggesting these women are unlikely to benefit from adjuvant chemotherapy.
Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
SALT LAKE CITY, April 23, 2019 -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it will hold its fiscal third-quarter 2019 sales.
The global medical device space takes significant strides in terms of research and development (R&D) and regulatory progress in the first quarter.
“We are focused on improving the lives of women with our pioneering science and are looking forward to presenting several exciting studies at ACOG this year,” said James Goldberg, M.D., board certified maternal fetal medicine specialist, medical geneticist and chief medical officer, Myriad Women’s Health. Please visit Myriad Women’s Health at booth #1041 to learn more about our leading portfolio of women’s health products.
Mid-caps stocks, like Myriad Genetics, Inc. (NASDAQ:MYGN) with a market capitalization of US$2.4b, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-cap stocks. Despite this...
Myriad Genetics, Inc. (MYGN), a global leader in personalized medicine, today announced today announced that the company was named to Forbes 2019 list of America's Best Midsize Employers for the third year in a row. “We are excited to again be recognized by both Forbes and the Women’s Tech Council for creating a company culture that empowers our employees to grow and become the best versions of themselves,” said Mark C. Capone, president and CEO, Myriad Genetics.